Ritholtz Wealth Management Boosts Stock Position in Thermo Fisher Scientific Inc. (NYSE:TMO)

Ritholtz Wealth Management boosted its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 7.0% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 3,908 shares of the medical research company’s stock after acquiring an additional 254 shares during the quarter. Ritholtz Wealth Management’s holdings in Thermo Fisher Scientific were worth $2,074,000 as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of TMO. Moneta Group Investment Advisors LLC boosted its holdings in Thermo Fisher Scientific by 104,536.8% during the 4th quarter. Moneta Group Investment Advisors LLC now owns 8,355,245 shares of the medical research company’s stock valued at $4,601,150,000 after acquiring an additional 8,347,260 shares during the period. Providence Capital Advisors LLC lifted its holdings in shares of Thermo Fisher Scientific by 61,754.7% in the 1st quarter. Providence Capital Advisors LLC now owns 5,842,175 shares of the medical research company’s stock worth $10,136,000 after buying an additional 5,832,730 shares during the period. Norges Bank purchased a new stake in shares of Thermo Fisher Scientific in the 4th quarter worth $3,105,677,000. Morgan Stanley lifted its holdings in shares of Thermo Fisher Scientific by 17.7% in the 4th quarter. Morgan Stanley now owns 11,730,063 shares of the medical research company’s stock worth $6,459,629,000 after buying an additional 1,764,312 shares during the period. Finally, Loomis Sayles & Co. L P lifted its holdings in shares of Thermo Fisher Scientific by 17,046.7% in the 3rd quarter. Loomis Sayles & Co. L P now owns 973,591 shares of the medical research company’s stock worth $492,803,000 after buying an additional 967,913 shares during the period. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Insider Transactions at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, SVP Michael A. Boxer sold 14,566 shares of the stock in a transaction that occurred on Wednesday, February 7th. The stock was sold at an average price of $562.00, for a total transaction of $8,186,092.00. Following the transaction, the senior vice president now owns 12,901 shares in the company, valued at $7,250,362. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction that occurred on Tuesday, March 12th. The stock was sold at an average price of $597.98, for a total transaction of $5,979,800.00. Following the completion of the transaction, the chief executive officer now owns 123,816 shares of the company’s stock, valued at $74,039,491.68. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Michael A. Boxer sold 14,566 shares of the stock in a transaction that occurred on Wednesday, February 7th. The shares were sold at an average price of $562.00, for a total value of $8,186,092.00. Following the transaction, the senior vice president now directly owns 12,901 shares of the company’s stock, valued at approximately $7,250,362. The disclosure for this sale can be found here. Insiders have sold 50,277 shares of company stock worth $28,513,384 over the last quarter. 0.32% of the stock is currently owned by insiders.

Analysts Set New Price Targets

Several research analysts have recently commented on the company. Raymond James boosted their price target on Thermo Fisher Scientific from $515.00 to $605.00 and gave the stock an “outperform” rating in a research report on Thursday, February 1st. Sanford C. Bernstein reissued a “market perform” rating on shares of Thermo Fisher Scientific in a research report on Monday, January 8th. Robert W. Baird reissued an “outperform” rating and issued a $670.00 price target on shares of Thermo Fisher Scientific in a research report on Thursday, December 14th. Barclays lowered Thermo Fisher Scientific from an “overweight” rating to an “equal weight” rating and boosted their price target for the stock from $475.00 to $555.00 in a research report on Wednesday, January 24th. Finally, Wolfe Research initiated coverage on Thermo Fisher Scientific in a research report on Wednesday, December 13th. They set an “outperform” rating and a $575.00 target price on the stock. Five investment analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $599.00.

Thermo Fisher Scientific Stock Performance

Shares of TMO stock traded up $1.84 during mid-day trading on Thursday, reaching $581.21. The stock had a trading volume of 1,034,640 shares, compared to its average volume of 1,617,943. The business’s fifty day moving average is $565.13 and its 200-day moving average is $520.22. The company has a current ratio of 1.75, a quick ratio of 1.39 and a debt-to-equity ratio of 0.67. The firm has a market cap of $221.62 billion, a price-to-earnings ratio of 37.63, a PEG ratio of 2.39 and a beta of 0.80. Thermo Fisher Scientific Inc. has a 1-year low of $415.60 and a 1-year high of $603.82.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings data on Wednesday, January 31st. The medical research company reported $5.67 earnings per share for the quarter, beating analysts’ consensus estimates of $5.64 by $0.03. Thermo Fisher Scientific had a return on equity of 18.78% and a net margin of 13.99%. The business had revenue of $10.89 billion for the quarter, compared to analyst estimates of $10.73 billion. During the same period in the prior year, the company earned $5.40 earnings per share. The company’s revenue was down 4.9% on a year-over-year basis. On average, research analysts forecast that Thermo Fisher Scientific Inc. will post 21.52 earnings per share for the current year.

Thermo Fisher Scientific Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, April 15th. Stockholders of record on Friday, March 15th will be paid a $0.39 dividend. This is an increase from Thermo Fisher Scientific’s previous quarterly dividend of $0.35. The ex-dividend date is Thursday, March 14th. This represents a $1.56 dividend on an annualized basis and a dividend yield of 0.27%. Thermo Fisher Scientific’s dividend payout ratio is presently 10.10%.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.